ADC Therapeutics SA
ADCT
$3.43
-$0.05-1.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 79.18M | 81.36M | 75.21M | 77.25M | 75.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.18M | 81.36M | 75.21M | 77.25M | 75.82M |
| Cost of Revenue | 100.02M | 107.52M | 116.87M | 122.22M | 116.81M |
| Gross Profit | -20.85M | -26.16M | -41.67M | -44.98M | -40.99M |
| SG&A Expenses | 82.03M | 80.23M | 79.67M | 81.33M | 83.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 182.05M | 187.75M | 196.54M | 203.55M | 200.10M |
| Operating Income | -102.88M | -106.40M | -121.33M | -126.30M | -124.29M |
| Income Before Tax | -136.14M | -141.61M | -165.84M | -168.76M | -149.67M |
| Income Tax Expenses | 850.00K | 1.02M | 1.10M | 1.19M | 168.00K |
| Earnings from Continuing Operations | -136.99 | -142.62 | -166.94 | -169.94 | -149.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -136.99M | -142.62M | -166.94M | -169.94M | -149.84M |
| EBIT | -102.88M | -106.40M | -121.33M | -126.30M | -124.29M |
| EBITDA | -102.34M | -105.69M | -120.28M | -124.92M | -122.94M |
| EPS Basic | -1.10 | -1.20 | -1.45 | -1.57 | -1.45 |
| Normalized Basic EPS | -0.60 | -0.66 | -0.82 | -0.89 | -0.90 |
| EPS Diluted | -1.10 | -1.20 | -1.45 | -1.57 | -1.45 |
| Normalized Diluted EPS | -0.60 | -0.66 | -0.82 | -0.89 | -0.90 |
| Average Basic Shares Outstanding | 527.66M | 507.69M | 462.79M | 431.17M | 413.12M |
| Average Diluted Shares Outstanding | 527.66M | 507.69M | 462.79M | 431.17M | 413.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |